EIEBFLA: The Effects of Intermittent Epidural Bolus on Fever During Labor Analgesia

Sponsor
ShanWu Feng, M.D. (Other)
Overall Status
Unknown status
CT.gov ID
NCT01708668
Collaborator
(none)
12,000
1
8
56
214.3

Study Details

Study Description

Brief Summary

Epidural analgesia is associated with maternal intra-partum fever during labor. Intermittent epidural injections appear to reduce the incidence of maternal intra-partum fever compared to continuous epidural infusion during labor analgesia. However, the optimal combination of bolus volume and administrating interval has not yet been compared. The purpose of this prospective, randomized, double-blind trial was to determine how intermittent epidural bolus reduced the incidence of maternal intra-partum fever compared with continuous epidural infusion during labor.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Epidural analgesia
  • Procedure: Combined spinal-epidural analgesia
  • Procedure: Continuous epidural infusion
  • Procedure: Intermittent epidural bolus
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
12000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Effects of Intermittent Epidural Bolus Versus Continuous Epidural Infusion on Fever for Labor Analgesia in Primiparous Women
Study Start Date :
Oct 1, 2012
Anticipated Primary Completion Date :
Jul 1, 2015
Anticipated Study Completion Date :
Jun 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: 1

Epidural analgesia (EA) with continuous epidural infusion(CEI)

Procedure: Epidural analgesia

Procedure: Continuous epidural infusion

Active Comparator: 2

Combined spinal-epidural analgesia (CSEA) with continuous epidural infusion(CEI)

Procedure: Combined spinal-epidural analgesia

Procedure: Continuous epidural infusion

Active Comparator: 3

Epidural analgesia (EA) with intermittent epidural bolus (IEB, 2.5 mL bolused every 15 minutes)

Procedure: Epidural analgesia

Procedure: Intermittent epidural bolus

Active Comparator: 4

Epidural analgesia (EA) with intermittent epidural bolus (IEB, 5ml bolused every 30 minutes)

Procedure: Epidural analgesia

Procedure: Intermittent epidural bolus

Active Comparator: 5

Epidural analgesia (EA) with intermittent epidural bolus (IEB, 10ml bolused every 60 minutes)

Procedure: Epidural analgesia

Procedure: Intermittent epidural bolus

Active Comparator: 6

Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 2.5 mL bolused every 15 minutes)

Procedure: Combined spinal-epidural analgesia

Procedure: Intermittent epidural bolus

Active Comparator: 7

Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 5ml bolused every 30 minutes)

Procedure: Combined spinal-epidural analgesia

Procedure: Intermittent epidural bolus

Active Comparator: 8

Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 10ml bolused every 60 minutes)

Procedure: Combined spinal-epidural analgesia

Procedure: Intermittent epidural bolus

Outcome Measures

Primary Outcome Measures

  1. Maternal oral and tympanic temperature [At time of initiation of analgesia and hourly thereafter until 4 hours postpartum (approximately 12 hours)]

Secondary Outcome Measures

  1. Maternal serum Interleukin-1β [At time of placental delivery and 3, 6 and 12 hours later]

  2. Cord serum Interleukin-1β [At time of placental delivery]

  3. Maternal serum Interleukin-6 [At time of placental delivery and 3, 6 and 12 hours later]

  4. Cord serum Interleukin-6 [At time of placental delivery]

  5. Maternal serum Interleukin-10 [At time of placental delivery and 3, 6 and 12 hours later]

  6. Cord serum Interleukin-10 [At time of placental delivery]

  7. Maternal serum tumor necrosis factor-α [At time of placental delivery and 3, 6 and 12 hours later]

  8. Cord serum tumor necrosis factor-α [At time of placental delivery]

  9. Regression and correlation analyses between maternal and cord serum cytokines [At twelve hours postpartum]

  10. Placental routine pathologic examination [At time of placental delivery]

  11. Maternal and cord blood gase analysis [At time of placental delivery]

  12. Maternal modified Bromage scale and visual analogue scale [At time of initiation of analgesia and hourly thereafter until 2 hours postpartum (approximately 10 hours)]

  13. Rescue boluses, n of rescue boluses, and the consumption of the ropivacaine/sufentanil mixture [At two hours postpartum]

  14. Rates of cesarean delivery and instrument-assisted delivery [At time of placental delivery]

  15. Indications of cesarean delivery [Initiation of analgesia to placental delivery (approximately 8 hours)]

  16. Duration of analgesia [Initiation of analgesia to 2 h postpartum (approximately 10 hours)]

  17. Durations of labor stages [From the beginning of regular contraction of uterus to the end of the labor (approximately 12 hours)]

  18. Maternal satisfaction with analgesia [At two hours postpartum]

  19. Use of oxytocin after analgesia [At twenty-four hours postpartum]

  20. Low back pain at 3 months after vaginal delivery [At the third month after vaginal delivery]

  21. Breastfeeding success at 6 weeks after vaginal delivery [At the sixth week after successful delivery]

  22. Neonatal Apgar scale [At the first and fifth minutes after baby was born]

  23. Incidence of maternal side effects [Initiation of analgesia to 2 hour postpartum (approximately 10 hours)]

  24. Neonatal Neurologic and Adaptive Capacity Score [At 30 min, 2 h, and 24 h after baby was born]

  25. Maximal oxytocin dose [At twenty-four hours postpartum]

  26. Neonatal sepsis evaluation [At 30 min after baby was born]

  27. Neonatal antibiotic treatment [One week after baby was born]

  28. Maternal heart rate, respiratory rate, and blood pressure [At time of initiation of analgesia and hourly thereafter until 4 hours postpartum (approximately 12 hours)]

  29. Highest thoracic sensory level to alcohol [At three hours after initiation of analgesia]

  30. Uterine contraction [At time of initiation of analgesia and hourly thereafter until 4 hours postpartum (approximately 12 hours)]

  31. Neonatal rectal temperature [At delivery, 30 min after delivery, and 1 h after delivery]

  32. Fetal heart rate [From initiation of analgesia to delivery (approximately 8 hours)]

  33. Maternal group B streptococcus (GBS) colonization [At time of initiation of analgesia]

  34. Number of vaginal examinations, duration from rupture of the membranes to delivery, mode of membranes ruptured [From initiation of analgesia to delivery (approximately 8 hours)]

  35. Neonatal weight [At delivery]

  36. Uterine artery, umbilical artery and vein, fetus middle cerebral artery by ultrasound [At time of initiation of analgesia and hourly thereafter until delivery (approximately 8 hours)]

  37. Maternal serum epinephrine, norepinephrine, insulin, glucagon, corticotropin releasing hormone, adrenocorticotropic hormone, cortisol, blood glucose, oxytocin, prostaglandin E2 and prostaglandin F2 alpha [At time of initiation of analgesia and hourly thereafter until 4 hours postpartum (approximately 12 hours)]

  38. Maternal postpartum depression [At time of delivery and daily thereafter until 1 year postpartum (approximately 1 year)]

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Nulliparous women

  • Required labor analgesia

  • Chinese

  • Spontaneous labor

Exclusion Criteria:
  • Contraindications for epidural analgesia

  • Allergic to opioids and/or local anesthetics

  • Failed to performing epidural catheterization

  • Organic dysfunction

  • Those who were not willing to or could not finish the whole study at any time

  • Using or used in the past 14 days of the monoamine oxidase inhibitors

  • Alcohol addictive or narcotic dependent patients

  • Subjects with a nonvertex presentation or scheduled induction of labor

  • Twin gestation and breech presentation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Nanjing Maternal and Child Health Care Hospital Affiliated to Nanjing Medical University Nanjing Jiangsu China 210004

Sponsors and Collaborators

  • ShanWu Feng, M.D.

Investigators

  • Study Director: Shanwu Feng, M.D., Nanjing Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
ShanWu Feng, M.D., Department of Anesthesiology, Nanjing Maternal and Child Health Care Hospital, Nanjing, Jiangsu, China, 210004, Nanjing Medical University
ClinicalTrials.gov Identifier:
NCT01708668
Other Study ID Numbers:
  • NJMCHH-2012-A010
  • 08NMUM063
  • YKK08119
  • YKK11058
First Posted:
Oct 17, 2012
Last Update Posted:
Jan 15, 2015
Last Verified:
Jan 1, 2015
Keywords provided by ShanWu Feng, M.D., Department of Anesthesiology, Nanjing Maternal and Child Health Care Hospital, Nanjing, Jiangsu, China, 210004, Nanjing Medical University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 15, 2015